Europe pharmacogenomics market accounted for $1,565.6 million in 2019 and will grow by 7.1% annually over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic.
Highlighted with 38 tables and 50 figures, this 125-page report “Europe Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country.
Based on Service, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Genotyping
• SNP Identification
• Diagnostics
• Other Services
Based on Technology, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Polymerase Chain Reaction (PCR)
• Microarray
• Sequencing
• Electrophoresis
• Mass Spectrometry
• Other Technologies
Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Oncology
• Infectious Diseases
• Neurology/Psychiatry
• Cardiovascular
• Pain Management
• Other Applications
Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Hospitals and Clinics
• Pharmaceutical Companies
• Research Institutes
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
23andMe, Inc.
Abbott Laboratories
Admera Health, LLC
Agena Biosciences, Inc.
Astra Zeneca PLC
Bayer AG
Becton, Dickinson and Company
Cancer Genetics, Inc.
Dynamic DNA Laboratories
Empire Genomics LLC
F. Hoffmann-La Roche Ltd
geneOmbio Technologies Pvt Ltd.
Genomic Health, Inc.
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics Inc.
Oneome LLC
Opko Health, Inc.
Pathway Genomics Corporation
QIAGEN N.V.
Quest Diagnostics Incorporated
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Transgenomic, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 31
2.4 Emerging Opportunities and Market Trends 34
2.5 Porter’s Fiver Forces Analysis 38
3 Segmentation of Europe Market by Service 42
3.1 Market Overview by Service 42
3.2 Genotyping 44
3.3 SNP Identification 45
3.4 Diagnostics 46
3.5 Other Services 48
4 Segmentation of Europe Market by Technology 49
4.1 Market Overview by Technology 49
4.2 Polymerase Chain Reaction (PCR) 51
4.3 Microarray 52
4.4 Sequencing 53
4.5 Electrophoresis 54
4.6 Mass Spectrometry 55
4.7 Other Technologies 56
5 Segmentation of Europe Market by Application 57
5.1 Market Overview by Application 57
5.2 Oncology 59
5.3 Infectious Diseases 60
5.4 Neurology/Psychiatry 61
5.5 Cardiovascular 63
5.6 Pain Management 64
5.7 Other Applications 65
6 Segmentation of Europe Market by End User 66
6.1 Market Overview by End User 66
6.2 Hospitals and Clinics 68
6.3 Pharmaceutical Companies 69
6.4 Research Institutes 70
7 European Market 2019-2030 by Country 71
7.1 Overview of European Market 71
7.2 Germany 74
7.3 UK 76
7.4 France 79
7.5 Spain 81
7.6 Italy 83
7.7 Russia 85
7.8 Rest of European Market 87
8 Competitive Landscape 89
8.1 Overview of Key Vendors 89
8.2 New Product Launch, Partnership, Investment, and M&A 93
8.3 Company Profiles 94
23andMe, Inc. 94
Abbott Laboratories 96
Admera Health, LLC 97
Agena Biosciences, Inc. 98
Astra Zeneca PLC 99
Bayer AG 100
Becton, Dickinson and Company 101
Cancer Genetics, Inc. 102
Dynamic DNA Laboratories 103
Empire Genomics LLC 104
F. Hoffmann-La Roche Ltd 105
geneOmbio Technologies Pvt Ltd. 106
Genomic Health, Inc. 107
Illumina, Inc. 108
Laboratory Corporation of America Holdings 109
Myriad Genetics Inc. 110
Oneome LLC 111
Opko Health, Inc. 112
Pathway Genomics Corporation 113
QIAGEN N.V. 114
Quest Diagnostics Incorporated 115
Teva Pharmaceuticals Industries Ltd. 116
Thermo Fisher Scientific Inc. 117
Transgenomic, Inc. 118
9 Investing in Europe Market: Risk Assessment and Management 119
9.1 Risk Evaluation of Europe Market 119
9.2 Critical Success Factors (CSFs) 122
Related Reports and Products 125
Key Players (this may not be a complete list and extra companies can be added upon request):
3M Health Care Limited
Adherium Limited
Amiko Digital Health Limited
AsthmaMD
AstraZeneca plc
Boehringer Ingelheim International GmbH
Capsule Technologies, Inc.
Cohero Health
GlaxoSmithKline plc
Kaia Health Software GmbH
Medical International Research (MIR)
Novartis AG
NuvoAir
Reciprocal Labs (Propeller Health)
Sensiron AG
Tactio Health
Teva Pharmaceuticals Industries Ltd.
*If Applicable.